Last updated: February 20, 2026
What is OXYCONTIN?
OXYCONTIN, the branded formulation of oxycodone extended-release, is an opioid analgesic approved by the U.S. Food and Drug Administration (FDA) in 1995. It is prescribed for managing severe chronic pain requiring around-the-clock treatment. The drug is produced by Purdue Pharma, which introduced it into the market.
Market Overview
Industry Context
The global opioid analgesics market was valued at around USD 13 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of approximately 4% from 2022 to 2028. However, increased regulatory scrutiny and litigation have impacted the supply chain and pricing dynamics.
Key Players
| Company |
Market Share (2022) |
Product Portfolio |
| Purdue Pharma |
Estimated 60% |
OXYCONTIN, other oxycodone formulations |
| Teva Pharmaceuticals |
Approx. 10% |
Generic oxycodone products |
| Mylan (now part of Viatris) |
Approx. 8% |
Generic options |
| Others |
Remaining share |
Various generics, regional players |
Regulatory and Legal Environment
Purdue Pharma filed for bankruptcy in 2019 amid thousands of lawsuits alleging role in opioid crisis. This has led to increased scrutiny of branding practices and pricing strategies. The company has settled multiple claims, impacting future market dynamics.
Pricing Data and Trends
Historical Pricing
| Year |
Average Wholesale Price (AWP) per 30 mg OXYCONTIN (USD) |
Notes |
| 2010 |
$4.50 |
Wide availability, stable pricing |
| 2015 |
$5.00 |
Slight increase, market growth |
| 2018 |
$5.80 |
Price hike prior to regulatory scrutiny |
| 2021 |
$7.20 |
Increased due to supply chain constraints |
Current Pricing (Q1 2023)
The average wholesale price for a 30 mg OXYCONTIN capsule stands at approximately USD 7.75. Pricing varies by geographic region, pharmacy, and insurance coverage.
Generic Competition Effect
Generic oxycodone extended-release formulations reduce prices by 25-35% compared to branded OXYCONTIN, depending on market conditions. The availability of generics since 2010 has suppressed the growth of branded formulations.
Market Drivers and Challenges
Drivers
- High demand for long-acting pain management options in chronic pain cases.
- Increasing use in post-surgical pain management.
- Market expansion into outpatient settings.
Challenges
- Regulatory restrictions on opioid prescribing.
- Litigation risks leading to strict distribution controls.
- Rising concerns regarding opioid addiction.
Price Projections (2023–2028)
| Year |
Estimated Average Wholesale Price (USD) per 30 mg capsule |
Assumptions |
| 2023 |
$7.80 — $8.20 |
Prices remain stable with slight annual increases |
| 2024 |
$8.00 — $8.50 |
Increased generic competition limits price increase |
| 2025 |
$7.50 — $8.00 |
Possible pricing pressure due to market saturation |
| 2026 |
$7.20 — $7.70 |
Market stabilizes with lower-end generic options |
| 2027 |
$6.80 — $7.50 |
Further generic proliferation and regulatory constraints |
| 2028 |
$6.50 — $7.20 |
Continued downward pressure, market adjustments |
Price declines are moderated by ongoing supply chain disruptions and regulatory constraints, which prevent steep reductions. A conservative projection anticipates gradual declines aligned with increased generic penetration.
Impact of Regulatory and Litigation Developments
Liability risks and regulatory controls could further suppress price growth. Purdue Pharma’s bankruptcy and restructuring may influence pricing by altering supply dynamics. State-level regulations limiting opioid prescriptions may lead to decreased demand, suppressing overall market prices.
Key Market Factors
- Reimbursement policies: Insurance coverage heavily influences retail prices.
- Abuse deterrence formulations: Innovations in formulation to prevent misuse could affect production costs.
- Market saturation: As generic options expand, prices tend to decrease.
Key Takeaways
- OXYCONTIN remains a high-demand, branded opioid pain medication, with market share eroding due to generics.
- Prices have declined from peak levels ($4.50 in 2010) to approximately $7.75 per 30mg capsule in 2023.
- Future pricing will stabilize or decline slightly, factoring in increased generic competition, regulatory restrictions, and litigation impacts.
- The opioid market faces persistent challenges, including regulatory oversight, litigation risks, and shifts toward non-opioid pain treatments.
FAQs
Q1: How does the presence of generics affect the price of OXYCONTIN?
Generic versions typically reduce the price of branded formulations by 25-35%, shrinking profit margins for Purdue Pharma and similar companies.
Q2: What are the main regulatory risks for OXYCONTIN?
Regulatory risks include restrictions on opioid prescribing, increased distribution controls, and potential litigation outcomes that could limit supply or impose financial penalties.
Q3: How do legal settlements influence the market?
Settlements involving Purdue Pharma and other opioid manufacturers have altered market dynamics by reducing supply, increasing manufacturing costs, or imposing restrictions on marketing.
Q4: What is the outlook for OXYCONTIN pricing in the next five years?
Prices are expected to stabilize or decline slightly due to rising generic competition and regulatory pressures, with a projected average wholesale price around USD 6.50–7.20 in 2028.
Q5: Are there any emerging competitors to OXYCONTIN?
Yes, numerous generic extended-release oxycodone products and newer non-opioid pain management therapies increasingly compete in the market.
References
[1] MarketsandMarkets. (2022). Opioid analgesics market by type, application, region - forecast to 2028.
[2] U.S. Food and Drug Administration. (2023). Opioid analgesics: Drug safety communication.
[3] Purdue Pharma. (2023). Company reports and market disclosures.
[4] IQVIA. (2022). Pharmaceutical market analysis.
[5] U.S. Department of Justice. (2022). Opioid litigation and settlement reports.
